: Friday, July 10, 2020
Korea‘s Bio Industry
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Nation split over WHO's decision on game addiction
The World Health Organiz...
[Startups to Watch] 'Noul aims to become major player in eradicating malaria'
Malaria, a mosquito-born...
[Photo News]Scenes at ASCO 2019
CHICAGO, Ill. -- The American Society of Cli...
Lee Han-soo, KBR correspondent
[Pre-ASCO 2019] Yooyoung Pharmaceutical: YYB101 -- refractory solid tumor treatment
[Pre-ASCO 2019] ABL Bio: ABL001- bispecific antibody with indications for anti-cancer therapy
[Pre-ASCO 2019] Samsung Bioepis: Ontruzant - HER2-positive breast cancer treatment
[Pre-ASCO 2019] Yuhan: Lazertinib -- non-small cell lung cancer treatment
The core of Yuhan’s anno...
Medical IT changes China's healthcare landscape
The advancement of infor...
[Interview with Global Pharmas] ‘Korea’s drug pricing an obstacle for providing optimal treatments to patients’
[Special] Patients issued 'ultimatum' to Gore. Why?
The artificial vessel su...
[Special]‘K-Medi’s overseas advance will contribute to health of global citizens’
[Special]‘We hope entire world will experience K-Care’
The Division of Global H...
Adolescent Protection Policy
E-mail address privacy
The Korean Doctors’ Weekly Co., Ltd.
76-1, Dongmak-ro, Mapo-gu, Seoul, Korea
Email : email@example.com
Title : Korea Biomedical Review
Online newspaper registration number : Seoul 아 04285
Date of registration : December 19, 2016
Publishing date : February 22, 2017
Publisher-Editor : Yang Kyung-cheol
Chief Executive Officer : Yang Kyung-cheol
Executive Editor : Choi Sung-jin
pyright © 2020 KBR. All rights reserved.
Back to Top